Yujin Bio-Pharma

Yujin Bio-Pharma (Wuhan Zhongsheng Yujin Biomedical Co., Ltd.) is a Chinese biopharmaceutical company and a subsidiary of the Wuhan Institute of Biological Products (WIBP), which is part of the China National Biotec Group (CNBG) and Sinopharm. Established in 2017 based on WIBP's Immunopreparation Department, the company specializes in the research, development, and manufacturing of therapeutic immunoglobulins. Its flagship commercial product is anti-human T lymphocyte porcine immunoglobulin (p-ATG), a unique biological immunosuppressant approved in China for the treatment of severe aplastic anemia (SAA) and used in renal transplantation immune induction. Yujin Bio-Pharma continues to expand its pipeline, exploring new applications for p-ATG in neuroinflammatory and autoimmune disorders such as multiple sclerosis and psoriasis, as well as developing rabbit-derived immunoglobulins.